On March 14, 2024 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that it filed regulatory applications with the Ministry of Health, Labour and Welfare for the anti-CD20xCD3 bispecific antibody mosunetuzumab for the treatment of patients with R/R FL who have received two or more prior systemic therapies (Press release, Chugai, MAR 14, 2024, View Source [SID1234641159]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Mosunetuzumab has shown promising results in clinical trials as monotherapy for achieving durable remissions. In addition, unlike previous treatments that require long-term continuous administration and hospitalization, the treatment period is predetermined, so it is expected to reduce the burden of hospital visits associated with treatment. We will continue working with the authorities to deliver this drug, which has the potential to change patients’ prognosis and social life, for patients as quickly as possible," said Dr. Osamu Okuda, Chugai’s President and CEO.

The application is based on the results of the Japanese phase I study and overseas Phase I/II study conducted by Roche in patients with R/R FL who had previously received two or more prior systemic therapies.